Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Nanchang UniversityActive in the last 2 years

Sisi Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1908-5054; OpenAlex author ID A5100341523. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 3

  1. Vaccinia-related kinase 2 inhibition elicits vulnerability of glutathione metabolism in pancreatic cancer. Co-author DOI 10.1038/s41419-026-08573-9↗
  2. Vaccinia-related kinase 2 drives pancreatic cancer progression by protecting Plk1 from Chfr-mediated degradation. Last author DOI 10.1038/s41388-021-01893-4↗
  3. Propofol attenuates pancreatic cancer malignant potential via inhibition of NMDA receptor. Co-author DOI 10.1016/j.ejphar.2016.12.017↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Long Liu · 1 shared paper, 2026 · strength 0.30
  2. Zhiyu Li · 1 shared paper, 2026 · strength 0.30
  3. Xiaowei Fu · 1 shared paper, 2026 · strength 0.30
  4. Hengqing Zhu · 1 shared paper, 2021 · strength 0.13
  5. Changhong Miao · 1 shared paper, 2017 · strength 0.08
  6. You Li · 1 shared paper, 2017 · strength 0.08
  7. Xiangyuan Chen · 1 shared paper, 2017 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.